+

WO2000059371A1 - Dispositif d'analyse a double fonction - Google Patents

Dispositif d'analyse a double fonction Download PDF

Info

Publication number
WO2000059371A1
WO2000059371A1 PCT/US2000/008530 US0008530W WO0059371A1 WO 2000059371 A1 WO2000059371 A1 WO 2000059371A1 US 0008530 W US0008530 W US 0008530W WO 0059371 A1 WO0059371 A1 WO 0059371A1
Authority
WO
WIPO (PCT)
Prior art keywords
assay device
optical
tissue
substance
energy
Prior art date
Application number
PCT/US2000/008530
Other languages
English (en)
Inventor
Danny F. Lincoln
Krishna S. Kumar
John J. Pasqua
Original Assignee
Spectrx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrx, Inc. filed Critical Spectrx, Inc.
Priority to US09/937,865 priority Critical patent/US6704587B1/en
Priority to CA002366746A priority patent/CA2366746A1/fr
Priority to MXPA01009830A priority patent/MXPA01009830A/es
Priority to AU40540/00A priority patent/AU4054000A/en
Priority to EP00919932A priority patent/EP1164923A1/fr
Priority to JP2000608939A priority patent/JP2003524462A/ja
Priority to BR0009468-4A priority patent/BR0009468A/pt
Publication of WO2000059371A1 publication Critical patent/WO2000059371A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
    • A61B5/14514—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02—Details of sensors specially adapted for in-vivo measurements
    • A61B2562/0295—Strip shaped analyte sensors for apparatus classified in A61B5/145 or A61B5/157
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents

Definitions

  • This invention relates to an apparatus and method for detecting substances including glucose in a fluid to be collected from tissue.
  • Glucose is an important substance for biological activities. For example, in individuals who may be affected by diabetes, there is a need to detect or measure the presence and amount of glucose as part of a daily routine.
  • currently available measurement techniques often involve invasive testing.
  • One method of glucose testing includes blood based assay testing.
  • the "finger stick" blood assay testing technique currently is one widely accepted methodology for glucose testing results in the United States.
  • this invasive approach requires that the drawing of blood to perform the test. This is quite uncomfortable to patients, especially to young patients. Moreover, this approach is time consuming.
  • the present invention is directed to a system and method for detecting substances, such as glucose, in a fluid to be collected from a tissue.
  • the system according to the present invention has an assay device and an optical apparatus.
  • the assay device is suitable for attachment to the tissue, wherein the assay device is a dual function device that includes a reactive region that is responsive to at least one substance in fluid to be collected from the tissue when the fluid is in contact with the reactive region, and which reactive region is also responsive to a first type of optical energy suitable to heat up and transfer heat by conduction to the tissue to ablate the tissue and form at least one opening in the tissue from which fluid is collected.
  • the optical apparatus has an activation head to which the assay device is attached, and a first optical energy source that outputs the first type of optical energy.
  • An optical detecting device is included in the optical apparatus to measure a characteristic of the at least one substance from the response of the reactive region when the reactive region is in contact with the at least one substance in fluid.
  • the present invention provides a method for detecting a substance, such as glucose, in a fluid from a tissue.
  • the method includes the steps of placing an assay on an activation head of an optical instrument, wherein the assay is responsive to at least one substance, positioning the activation head to the surface of the tissue so that the assay is in contact with the surface of the issue, forming at least one opening underneath the assay through the surface of the tissue, thereby to allow the fluid from the tissue to flow through the at least one opening and make contact with the assay, and detecting the response of the assay to the fluid to measure the presence of the at least one substance in the fluid.
  • the method can be practiced by using the system in accordance with a preferred embodiment of the present invention.
  • an assay device includes a base having a first side and a second side, and a reactive region disposed or deposited on the first side of the base.
  • the reactive region comprises a photosensitizing material that is placed in contact with the surface of the tissue and is responsive to a suitable electromagnetic energy emitted thereon so as to heat up and conductively transfer heat to the surface of the tissue to form at least one opening, thereby to allow fluid from the tissue through the at least one opening to contact with the assay.
  • the photosensitizing material is further responsive to at least one substance in the fluid, from which a characteristic of the at least one substance is detected based upon electromagnetic energy scattered and/or reflected therefrom.
  • FIG. 1 is a schematic diagram of a system for detecting at least one substance in a fluid to be collected from a tissue according to the present invention.
  • FIG. 2 shows a first side of an assay device in connection with the system shown in Fig. 1 according to the present invention.
  • FIG. 3 shows a second side of an assay device in connection with the system shown in Fig. 1 according to the present invention.
  • FIG. 4 shows a cross-sectional side view of an assay device in connection with the system shown in Fig. 1 according to the present invention.
  • FIG. 5 is a flow chart generally depicting the overall process employing the method according to the present invention.
  • FIG. 6 shows a cross-sectional, partial view of the assay device and activation head of the optical apparatus shown in Fig. 1 in operation.
  • FIG. 7 shows a cross-sectional, bottom view of a first embodiment of an activation head of the optical apparatus shown in Fig. 1 according to the present invention.
  • FIG. 8 shows a cross-sectional, bottom view of a second embodiment of an activation head of the optical apparatus shown in Fig. 1 according to the present invention.
  • biological fluid or “fluid” at least includes “interstitial fluid” (ISF), which is the clear fluid that occupies the space between the cells in the body, or blood.
  • ISF interstitial fluid
  • tissue means an aggregate of cells of a particular kind, together with their intercellular substance, that form a structural material of an animal or plant. At least one surface of the tissue must be accessible to electromagnetic radiation so that the invention can be carried out.
  • the preferred tissue is the skin.
  • Other tissues suitable for use with this invention include mucosal tissue and soft organs.
  • glucose means a monosaccharide also known as D- glucose, D-glucopyranose, grape sugar, corn sugar, dextrose, and cerelose. Glucose occurs in the animal body fluids, for example, in blood, lymphy, or interstitial fluid. Glucose enters the bloodstream by absorption from the small intestine. It is carried via the portal vein to the liver, where part is stored as glycogen, the remainder reentering the circulatory system. Another site of glycogen storage is muscle tissue.
  • analyte means a component that is being detected or measured in an analysis.
  • the analyte may be any chemical or biological material or compound suitable for passage through a biological membrane technology known in the art, of which an individual might want to know the concentration or activity inside the body.
  • Glucose is a specific example of an analyte because it is a sugar suitable for passage through the skin.
  • Individuals, for example those having diabetes, might want to know their blood glucose levels.
  • Other examples of analytes include, but are not limited to, such compounds as sodium, potassium, billirubin, urea, ammonia, calcium, lead, iron, lithium, salicylates, pharmaceutical compounds, and the like.
  • hole or microporation means the formation of a small hole or pore or opening to a desired depth in or through the biological membrane, such as skin or mucous membrane, or the outer layer of an organism to lessen the barrier properties of this biological membrane to the passage of biological fluids, such as analytes from below the surface for analysis.
  • the hole or micropore will be no larger than about 1 mm (1000 ⁇ m) in diameter, and will extend to a selected depth, as described hereinafter.
  • micropore or “pore” means an opening formed by the microporation method.
  • the term "reagent,” “active component,” or any other similar term means any chemical material or compound suitable for use by the methods previously known in the art and/or by the methods taught in the present invention, that induces a desired effect, such as a biological, or optical effect, or other observable effect, which may include but is not limited to (1) producing a detectable shift in this compound or formulation's measurable response to the application of energy to this area which may be electromagnetic, mechanical, thermal, optical or acoustic when in contact with at least one substance in a fluid to be collected from a tissue, (2) producing a response when in contact with at least one substance in a fluid to be collected from a tissue so as to allow a characteristic of the at least one substance can be measured or detected from the response; and/or (3) being responsive to a type of electromagnetic energy emitted thereon when in contact with a tissue to heat up and transfer heat by conduction to the issue to ablate the
  • photosensitizing material means a material that contains at least one reagent or active component, which at least is responsive to at least one substance in a fluid and to a type of electromagnetic energy emitted thereon when in contact with a tissue to heat up and transfer heat by conduction to the issue to ablate the tissue.
  • the present invention is directed to a system and method for detecting at least one substance in a fluid to be collected from a tissue.
  • the system and method are described in connection with an application for detecting glucose in interstitial fluid or blood collected from a human being.
  • the system and method according to the present invention can be used to detect other substance(s) in any biological fluids.
  • Fig. 1 shows a system 100 which utilizes a disposable assay device 20 in combination with an optical apparatus 50 for detecting a substance such as glucose in a fluid to be collected from a tissue 40.
  • the optical apparatus 50 includes a housing 52 that is approximately the size of a human hand.
  • a first energy source 54, a second energy source 56, and a detecting instrument 58 are located inside housing 52.
  • First energy source 54, second energy source 56, and detecting instrument 58 are coupled to an activation head 70 via optical fiber (s) 60.
  • Activation head 70 is received in an open end 74 of a holder 72 of housing 52.
  • Holder 72 can have any shape depending, among other things, on the shape of activation head 70 and hence may alternatively be referred to as an activation head receiving element.
  • holder 72 is cone-shaped. Holder 72 can be a separate piece or part of housing 52. It is preferable that holder 72 be capable of receiving activation head 70, to allow a glucose measurement to be made by using a disposable assay device 20, but then allowing disposable assay device 20 to be readily removed after a measurement performed, and then allowing a new assay device 20 to be attached to the activation head 70 again so that system 100 is ready to perform a new measurement.
  • the optical apparatus 50 shown in Fig. 1 is derived from an apparatus disclosed in commonly assigned U.S. Patent No. 5,792,049, which is incorporated herein by reference.
  • first energy source 54 transmits a first type of energy in the form of electromagnetic radiation 39 with sufficient intensity.
  • the first energy source 54 is an optical energy source, such as a laser, that provides stimulated emission of radiation and operates in the infrared, visible, or ultraviolet region and is suitable for practicing the present invention.
  • the first energy source 54 can be a laser diode, a radio signal generator, a microwave signal generator, an acoustic signal generator, a visible signal generator, an ultraviolet signal generator, an x-rays generator, a ⁇ -rays generator, an -rays generator, a ⁇ -rays generator, or any other type of electromagnetic signal generator.
  • the second energy source 56 provides a second type of energy as output to a subject, i.e., the assay device 20.
  • the second energy source 56 is an optical energy source such as a light bulb, a tungsten halogen bulb, a noble gas filled tungsten bulb, one or several LEDs, or other similar optical devices covering the desired regions of a target optical spectrum.
  • the second energy source 56 transmits the second type of energy to the activation head 70 through optical fiber(s) 60.
  • the activation head 70 projects the second type of energy onto the assay device 20.
  • the second energy source 56 can be placed at a location within housing 52 and near the holder portion 72 to output the second type of energy to the assay device 20 directly.
  • the optical energy is output to the assay device 20 through the activation head 70 to illuminate the assay device 20, which is in contact with fluid from the tissue 40.
  • Optical energy scattered and/or reflected from the assay device 20 can be collected and transmitted to the detecting instrument 58 through activation head 70 to detect and/or measure the presence of at least one substance in the fluid from the tissue 40, such as glucose.
  • first and second energy sources 54, 56 are separate elements, it is also envisioned that a single energy source may provide both first and second types of energy.
  • An example of such an energy source is a laser with an adjustable intensity and bandwidth.
  • the optical apparatus 50 can include a control unit (not shown) to control application of the first type of energy from the first energy source 54, the second type of energy from the second energy source 56 and processing of energy received by the detecting instrument 58.
  • detecting instrument 58 is an optical detecting device, such as a spectrometer.
  • the spectrometer can, for example, include a microspectrometer offered by American Laubscher Corporation of Farmingdale, New York, called the NIS/NIP microspectrometer.
  • the detecting instrument 58 can be other kinds of electromagnetic signal detectors such as specified band detector(s).
  • the detecting instrument 58 is coupled to the activation head 70 through one of the optical fibers 60 to detect and/or measure a characteristic of at least one substance such as glucose in a fluid collected from the tissue 40 based on energy spectrum corresponding to an interaction between the assay device 20 and the glucose in a fluid collected from the tissue 40.
  • the energy spectrum includes electromagnetic energy scattered and/or reflected from the assay device 20 which is irradiated by at least one of the first energy source 54 and the second optical energy source 56.
  • the energy spectrum includes light within a waveband indicative of the substance, such as glucose, in the fluid scattered and/or reflected from the assay device 20, and the desirable optical interaction can include the appearance and/or change of color (visible or invisible) in a region of the assay device 20.
  • the presence of a substance can be measured if the energy spectrum detected by the detecting instrument 58 does not have a component with a specific waveband otherwise indicative of the substance.
  • the presence of a substance in a fluid can be measured using Fluorescence intensity, Fluorescence lifetime, surface plasmon resonance, Fluorescence polarization, circular dichroism, Raman scattering and other known technologies, or a combination of at least two of these technologies in conjunction with the embodiments of the present invention.
  • the assay device 20 has a reactive region that is responsive to glucose and in contact with the fluid as discussed in more detail below.
  • the detecting instrument 58 preferably has a sensor (not shown) responsive to energy reflected from and/or scattered by the assay device 20, and a processor (not shown) coupled to the sensor for receiving and processing an output of the sensor to determine the presence of the at least one of the substances. Further a display (LCD or other type) disposed on the exterior of the optical apparatus 50 may be coupled to the detecting instrument to display a measurement.
  • Optical fiber(s) 60 can be a single flexible transparent fiber device containing a bundle of optical fibers or a bundle of flexible transparent fiber devices.
  • optical fiber(s) 60 are light guides having fiber properties and requirements for image transfer, in which information is continuously transmitted over relatively short distances.
  • Optical fiber(s) 60 can be any one, or a combination of multimode, stepped refractive index profile fibers, graded index multimode fiber, and a single-mode, stepped index fiber.
  • optical fiber(s) 60 is a single or combination of multimode, stepped refractive index profile fibers.
  • optical fibers made by 3M Corporation having a diameter range of 1-1000 microns, can be used to practice the present invention.
  • optical fiber(s) In one embodiment of the present invention as shown in Fig. 7, optical fiber(s)
  • optical fiber(s) 60 includes optical fibers 60a, 60b, and 60c for electromagnetic energy transmission for the first energy source 54, the second energy source 56 and the detecting instrument 58, respectively.
  • optical fiber(s) 60 includes a bundle of several flexible transparent fiber devices 60a, 60b, and 60c.
  • optical fiber 60a couples the first energy source 54 to the activation head 70
  • optical fibers 60b couple the second energy source 56 to the activation head 70
  • optical fibers 60c couple the detecting instrument 58 to the activation head 70.
  • curved portion 66 of housing 52 allows a user's hand to comfortably hold and position system 100 which includes the optical apparatus 50 with attached assay device 20 so as to press the assay device 20 firmly against the tissue 40 to conduct a measurement.
  • a person can initiate a measurement as the case may be, by pressing a push button 61 with his or her thumb.
  • the activation head 70 has a concavely-curved portion 71, as shown in Fig. 6. Note that Fig. 6 shows for explanatory purposes the activation head 70 being spaced from the tissue 40; in actual operation, the assay device 20 is attached to the activation head 70 and is in contact with the tissue 40.
  • a concavely-shaped activation head 70 allows the assay device 20 closely in contact with the tissue 40 when the assay device 20 is pressed against the tissue 40 by the activation head 70.
  • the activation head 70 is preferably made of material suitable for absorbing heat from the tissue generated by the reactive region 24 during operation.
  • the activation head 70 thus serves as a heat sink to reduce the sensation to the subject, such as a patient, by removing the heat from the tissue incidentally created during the operation process.
  • the material of the activation head 70 is aluminum or other suitable metals or alloys that have good heat sinking characteristics.
  • the assay device 20 includes a base or support member 21 having a first side 22 and a second side 32.
  • the base 21 can be a small disk-shaped member made from fiber or other suitable material(s) transparent to the first and second types of energy output by the first and second energy sources 54, 56.
  • base 21 can be oval, square, triangular, or any other geometric shape.
  • base 21 can be made from plastics, polymers, thin film of metal, paperboards, or other types of materials. As shown in Figs.
  • the first side 22 of the assay device 20 has a reactive region 24 or a microdot disposed or deposited on the first side 22.
  • the reactive region 24 is substantially located at the center area of the first side 22.
  • the reactive region 24 includes a layer of photosensitizing material, which is responsive to the electromagnetic energy output by the first energy source 54 so as to heat up and conductively transfer heat to the surface of the tissue 40 to form at least one opening or micropore 41 as shown in Fig. 6, thereby to allow fluid from the tissue 40 through the at least one opening or micropore 41 to contact with the first side 22 of the assay device 20.
  • This microporation technique is described in commonly assigned U.S. Patent No.
  • the reactive region 24 or the layer of photosensitizing material is responsive to a substance of interest in the fluid, to alter in a detectable manner electromagnetic energy scattered by and/or reflected from the reactive region 24 in response to application of the second type of optical energy thereby indicating a characteristic of the at least one of the substances in the tissue 40.
  • the first side 22 of the assay device 20 optionally has adhesive material 26 disposed or deposited thereon as to leave the reactive region 24 substantially uncovered, as shown in Fig. 2.
  • the adhesive material 26 can be used to attach the assay device 20 to the tissue 40 when the activation head 70 presses the assay device 20 to the tissue 40.
  • the assay device 20 optionally has adhesive material 36 deposited on the second side 32.
  • the adhesive material 36 can be used to attach the assay device 20 to the activation head 70 of the optical apparatus 50.
  • the adhesive material 36 is disposed on the base 21 to form a mask around a window 34 opposite the reactive region 24 of the first side 22.
  • the window 34 allows the output electromagnetic energy 39a from the first energy source 54, such as a laser, to reach and heat up the reactive region 24 of the first side 22, which then transfers heat 39c' to the surface of the tissue 40 to form at least one opening or a micropore 41 as shown in Fig. 6, thereby to allow fluid from the tissue through the at least one opening 41 to contact with the reactive region 24 of the first side 22.
  • the window 34 also allows the output electromagnetic energy 39b from the second energy source 56 to reach the reactive region 24 and cause a desirable optical interaction with the reactive region 24 that can then be detected from scattered by and/or reflected energy 39c, as explained above.
  • the assay device 20 has a tear tab 28.
  • Tear tab 28 can be an integral part of the base 21, or a separate component attached to the base 21 by glue or other kind of adhesive material or heat sealing, etc. Tear tab 28 can be used to handle or transport the assay device 20, prior, during or after a measurement. For example, prior to a measurement to be performed, tear tab 28 can be used to attach the assay device 20 to the activation head 70 of the optical apparatus 50. Likewise, once a measurement has been performed, tear tab 28 can be used to peel the assay device 20 away from the activation head 70. A new assay device 20 can then be attached to the activation head 70 and system 100 is now ready to make another measurement on tissue 40.
  • the photosensitizing material used in the reactive region 24 preferably includes a formulation of active components and/or inactive components.
  • the formulation of the photosensitizing material provides at least two functions: one function to react with one or more substances of interest to allow for detection thereof by electromagnetic means; and a second function to absorb a certain type of electromagnetic energy focused thereon to heat up and conductively transfer heat to adjacent tissue and form at least one opening therein.
  • the inactive components include a number of well-known polymeric binders that can both stabilize and hold the active components in place. These polymeric binders include, but are not limited to, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, bovine serum albumin, and collagen.
  • a surfactant that will allow for more even spreading and quicker re-solubilization of the active components can be added as an inactive component.
  • the surfactant suitable for the present invention such as sodium dodecyl sulfate, Triton X- 100, cholate, dioctylsulfosuccinate, polyoxyethylenesorbitans such as Tween 20 and Span 20; and polyoxyethylene ethers such as Brij 35, etc.
  • a buffer can be included in the formulation as an inactive component.
  • Commonly used buffers are citrate, phosphate and a variety of "biological buffers" such as HEPES, MES, Bis-Tris, BES, ADA, ACES, MOPSO, MOPS, Bis-Tris propane, TES, etc.
  • HEPES citrate
  • MES Bis-Tris
  • BES Bis-Tris
  • ADA ADA
  • ACES ACES
  • MOPSO MOPSO
  • MOPS Bis-Tris propane
  • TES Bis-Tris propane
  • the addition of a buffer to the formulation can improve the stability and performance of the photosensitizing material.
  • the choice of the buffer system will greatly depend on the choice of an indicator system as discussed below.
  • the active components of the layer of photosensitizing material include an enzyme system and an indicator of the at least one of the substances in the tissue 40 to be measured.
  • the active components include specific enzymes or compounds with a high binding affinity for glucose and can include an auxiliary enzyme or mediator. These components are used in conjunction with one or more indicators such as chromogens or fluorescent probes to produce a change in the absorption or absorption and emission spectra, respectively.
  • One enzyme system that is useful in a preferred embodiment of the present invention is the glucose oxidase ⁇ peroxidase system.
  • This enzyme system can be used in conjunction with a variety of indicators such as either 4-aminoantipyrine (4-AAP) or 3-methyl-2-benzothiazolone hydrazone (MBTH) with a variety of derivatives of phenol or aniline.
  • these derivatives include phenol, p-hydroxybenzoic acid, p- hydroxybenzene sulfonate, aniline, N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethyl aniline, N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methyl aniline, N-ethyl-N-(2-hydroxy- 3-sulfopropyl) aniline, N-(2-hydroxy-3-sulfopropyl) aniline, etc.
  • Some indicator systems that can be used with the glucose oxidase ⁇ peroxidase system require just one chromogen and can be used without 4-AAP or MBTH.
  • Examples of such indicators are ortho-dianisidine, ortho-toluidine, 3,3',5,5'-tetramethylbenzidine, ABTS and others.
  • Another enzyme system that is useful in a preferred embodiment of the present invention is glucose dehydrogenase and NAD.
  • This enzyme system can either be used as is with ultraviolet detection of NADH or coupled with either an electron mediator (or diaphorase) with a chromogen.
  • the electron mediator can come form the class of compounds such as ferrocyanide, phenazine methosulfate or phenazine ethosulfate.
  • the indicator can be one of the common tetrazolium dyes, such as iodo- nitrotetrazolium, neo-tetrazolium blue, nitro-tetrazolium blue or some of the newer water-soluble tetrazoliums (WSTs).
  • stains dye and pigments
  • cytological staining can be used with either the glucose oxidase/peroxidase system or the glucose dehydrogenase system to serve the function of absorbing electromagnetic (optical) energy of the first type to form openings in the tissue, as described above.
  • glucose binding proteins can be used in a preferred embodiment of the present invention. Such glucose binding proteins are nondestructive and are based on a signal change upon glucose binding.
  • the glucose detecting system that utilizes glucose binding proteins as active components is commonly fluorescence based.
  • At least two types of glucose binding proteins can be used in the present invention. One is a single molecule system, and the other is a bimolecular or multimolecular system.
  • the binding molecule has conjugated to it two fluorophores with the property that the emission spectrum of one of the fluorescent dyes (donor) overlaps with the absorption spectrum of the other dye (acceptor).
  • the binding molecule Upon binding there is a usually a conformational change in the protein molecule that changes the relative distance between the two dyes. Typically, the dyes move closer to each other.
  • Glucose binding proteins that are candidates for this type of work are Glucose-Galactose Binding Protein (GGBP), hexokinase (in the absence of ATP) and apo-glucose oxidase.
  • FRET Fluorescence Resonance Energy Transfer
  • a macromolecule that includes a single or multiple glucose molecule(s) is conjugated with a donor or acceptor fluorescent dye. While a glucose binding protein is conjugated with the other dye, i.e., if the glucose bearing molecule is conjugated with a donor dye, then the glucose binding protein is conjugated with the acceptor dye.
  • a common glucose binding protein used in this application is Concanavalin A.
  • Other lectins and GGBP, hexokinase and apo-glucose oxidase can also be used to bind glucose in this system.
  • the amount of FRET that occurs in this bimolecular system is proportional to the glucose concentration and is measured in the same ways as in the monomolecular system described above.
  • the photosensitizing material is disposed or deposited onto the base 21 as a thin film, or as a microdot, as known to those skilled in the art, or as an aggregation of powders containing a formulation of inactive components and active components as described above.
  • the reactive region 24 is formed and defined by the photosensitizing material.
  • FIG. 5 depicts the steps involved for using system 100 to perform a measurement on tissue 40 according to the present invention.
  • step 502 involves placing an assay device 20 on activation head 70 of optical apparatus 50.
  • the assay device 20 is responsive to at least one substance in a fluid from tissue 40.
  • system 100 is used to measure the presence of glucose in a fluid to be collected from tissue 40; in this case the assay device 20 is responsive to glucose.
  • the adhesive material 36 attaches the assay device 20 to the activation head 70 to maintain a proper position during the measurement.
  • Step 504 involves positioning the activation head 70 to the surface of the tissue 40 so that the assay device 20 is in contact with the surface of the tissue 40. It is preferable to press the activation head 70 firmly but gently against the tissue 40 so that the reactive region 24 is in direct contact with the surface of the tissue 40.
  • Step 506 involves forming at least one opening or micropore 41 underneath the assay 20 through the surface of the tissue 40, thereby to allow the fluid from the tissue 40 to flow through the at least one opening 41 and make contact with the assay 20 so as to wet the reactive region 24.
  • step 506 involves irradiating the reactive region 24 of the base 21 with energy 39a, whereby the photosensitizing material in the reactive region 24 is responsive to the energy 39a so as to heat up and conductively transfer heat 39c' to the surface of the tissue 40 to form the at least one opening 41.
  • multiple openings or micropores spaced apart from each other in the tissue may be formed.
  • the micropore is formed through a surface of the tissue, such as skin, to a predetermined depth range into the tissue.
  • One type of depth control of the micropore is described in more detail in commonly assigned U.S. Patent No. 6,022,316, which is incorporated herein by reference.
  • Step 508 involves detecting the response of the assay device 20 to the fluid to measure the presence of the at least one of the substances in the tissue 40.
  • step 508 involves irradiating the assay device 20 with energy, such as optical energy 39b or light from the second energy source 56, detecting energy 39c reflected and/or scattered from the reactive region 24 of the assay device 20, and evaluating the reflected and/or scattered energy 39c to determine the presence (and/or measurement) of the at least one substance in the tissue 40.
  • the detection can be performed by an optical instrument or detecting unit 58.
  • the assay device 20 can be removed from the optical apparatus 50 and disposed. Steps 502-508 as discussed above can then be repeated to perform a new measurement.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Investigating Or Analyzing Materials Using Thermal Means (AREA)

Abstract

Cette invention concerne un système et un procédé permettant de détecter la présence de substances telles que du glucose dans un tissu. Ce système comprend un dispositif d'analyse et un appareil optique. Le dispositif d'analyse comprend une zone de réaction qui réagit à la présence d'au moins une substance présente dans le liquide à extraire du tissu lorsque ce liquide est en contact avec la zone de réaction, laquelle zone réagit également à un premier type d'énergie optique appropriée pour émettre de la chaleur et la transférer par conduction au tissu à retirer par ablation et former au moins une ouverture dans le tissu dont le liquide a été extrait. L'appareil optique comporte une tête d'actionnement sur laquelle est fixé le dispositif d'analyse et une première source d'énergie qui fournit un premier type d'énergie optique. Cet appareil optique est assorti d'un dispositif de détection optique qui mesure une caractéristique d'au moins une substance à partir de la réponse de la zone de réaction en contact avec cette substance.
PCT/US2000/008530 1999-04-01 2000-03-31 Dispositif d'analyse a double fonction WO2000059371A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US09/937,865 US6704587B1 (en) 1999-04-01 2000-03-31 Dual function assay device
CA002366746A CA2366746A1 (fr) 1999-04-01 2000-03-31 Dispositif d'analyse a double fonction
MXPA01009830A MXPA01009830A (es) 1999-04-01 2000-03-31 Dispositivo de ensaye de doble funcion.
AU40540/00A AU4054000A (en) 1999-04-01 2000-03-31 Dual function assay device
EP00919932A EP1164923A1 (fr) 1999-04-01 2000-03-31 Dispositif d'analyse a double fonction
JP2000608939A JP2003524462A (ja) 1999-04-01 2000-03-31 ２機能分析デバイス
BR0009468-4A BR0009468A (pt) 1999-04-01 2000-03-31 Sistema para detectar pelo menos uma substância em um fluido a ser coletado de um tecido, método para detectar uma substância em um fluido de um tecido, aparelho para detectar substâncias, incluindo glicose, no tecido, e, dispositivo de ensaio para detectar peso molecular de uma substância de um fluido a ser coletado de um tecido

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12744299P 1999-04-01 1999-04-01
US60/127,442 1999-04-01

Publications (1)

Publication Number Publication Date
WO2000059371A1 true WO2000059371A1 (fr) 2000-10-12

Family

ID=22430139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008530 WO2000059371A1 (fr) 1999-04-01 2000-03-31 Dispositif d'analyse a double fonction

Country Status (7)

Country Link
EP (1) EP1164923A1 (fr)
JP (1) JP2003524462A (fr)
AU (1) AU4054000A (fr)
BR (1) BR0009468A (fr)
CA (1) CA2366746A1 (fr)
MX (1) MXPA01009830A (fr)
WO (1) WO2000059371A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075575A1 (fr) 2009-12-17 2011-06-23 Bayer Healthcare Llc Systèmes, dispositifs et procédés transdermiques pour l'analyse optique d'une substance à analyser
WO2011084607A1 (fr) 2009-12-17 2011-07-14 Bayer Healthcare Llc Systèmes, dispositifs, et méthodes transdermiques pour analyses biologiques
US8281675B2 (en) 2007-10-17 2012-10-09 Syneron Medical Ltd Dissolution rate verification
US8337493B2 (en) 2002-04-19 2012-12-25 Syneron Medical Ltd Handheld transdermal drug delivery and analyte extraction
US9011419B2 (en) 2007-12-05 2015-04-21 Syneron Medical Ltd Disposable electromagnetic energy applicator
US9037229B2 (en) 2007-10-09 2015-05-19 Syneron Medical Ltd Magnetic patch coupling
US9504826B2 (en) 2009-02-18 2016-11-29 Syneron Medical Ltd Skin treatment apparatus for personal use and method for using same
CN107928681A (zh) * 2017-12-12 2018-04-20 天津大学 一种基于耳垂血液层的微波能量谱无创血糖浓度检测法
CN112972884A (zh) * 2021-03-18 2021-06-18 河南省肿瘤医院 一种肿瘤科用智能敷药装置
WO2023009068A3 (fr) * 2021-07-26 2023-04-06 Ams-Osram Asia Pacific Pte. Ltd. Capteur de flux optique

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7787923B2 (en) * 2003-11-26 2010-08-31 Becton, Dickinson And Company Fiber optic device for sensing analytes and method of making same
WO2016015270A1 (fr) * 2014-07-31 2016-02-04 Empire Technology Development Llc Surveillance du glucose en temps reel

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792049A (en) 1996-01-17 1998-08-11 Spectrx, Inc. Spectroscopic system with disposable calibration device
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US6022316A (en) 1998-03-06 2000-02-08 Spectrx, Inc. Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5792049A (en) 1996-01-17 1998-08-11 Spectrx, Inc. Spectroscopic system with disposable calibration device
US6022316A (en) 1998-03-06 2000-02-08 Spectrx, Inc. Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8337493B2 (en) 2002-04-19 2012-12-25 Syneron Medical Ltd Handheld transdermal drug delivery and analyte extraction
US9037229B2 (en) 2007-10-09 2015-05-19 Syneron Medical Ltd Magnetic patch coupling
US8281675B2 (en) 2007-10-17 2012-10-09 Syneron Medical Ltd Dissolution rate verification
US9011419B2 (en) 2007-12-05 2015-04-21 Syneron Medical Ltd Disposable electromagnetic energy applicator
US9504826B2 (en) 2009-02-18 2016-11-29 Syneron Medical Ltd Skin treatment apparatus for personal use and method for using same
WO2011075575A1 (fr) 2009-12-17 2011-06-23 Bayer Healthcare Llc Systèmes, dispositifs et procédés transdermiques pour l'analyse optique d'une substance à analyser
WO2011084607A1 (fr) 2009-12-17 2011-07-14 Bayer Healthcare Llc Systèmes, dispositifs, et méthodes transdermiques pour analyses biologiques
US9354226B2 (en) 2009-12-17 2016-05-31 Ascensia Diabetes Care Holdings Ag Transdermal systems, devices, and methods to optically analyze an analyte
CN107928681A (zh) * 2017-12-12 2018-04-20 天津大学 一种基于耳垂血液层的微波能量谱无创血糖浓度检测法
CN107928681B (zh) * 2017-12-12 2020-07-21 天津大学 一种基于耳垂血液层的微波能量谱无创血糖浓度检测法
CN112972884A (zh) * 2021-03-18 2021-06-18 河南省肿瘤医院 一种肿瘤科用智能敷药装置
WO2023009068A3 (fr) * 2021-07-26 2023-04-06 Ams-Osram Asia Pacific Pte. Ltd. Capteur de flux optique

Also Published As

Publication number Publication date
CA2366746A1 (fr) 2000-10-12
BR0009468A (pt) 2002-02-05
AU4054000A (en) 2000-10-23
MXPA01009830A (es) 2002-11-04
JP2003524462A (ja) 2003-08-19
EP1164923A1 (fr) 2002-01-02

Similar Documents

Publication Publication Date Title
US6704587B1 (en) Dual function assay device
TWI283570B (en) Physiological sample collection devices and methods of using the same
EP1015887B1 (fr) Systemes transdermiques non invasifs servant a detecter des analytes
CA2506942C (fr) Dispositif de test de liquide biologique
US7731900B2 (en) Body fluid testing device
US9354226B2 (en) Transdermal systems, devices, and methods to optically analyze an analyte
US20100049016A1 (en) Noninvasive Transdermal Systems for Detecting an Analyte in a Biological Fluid and Methods
US20040203164A1 (en) Optical component based temperature measurement in analyte detection devices
JP2001506141A (ja) 分析物経皮モニタリングを行う方法および装置
EP1164923A1 (fr) Dispositif d'analyse a double fonction
JP2003524462A5 (fr)
JP2005526953A (ja) エンボス加工されたテストストリップシステム
JP2002122562A (ja) 唾液用バイオセンサ
AU2002300167B2 (en) Noninvasive Transdermal Systems for Detecting Analytes
US20130102065A1 (en) Small Volume and Fast Acting Optical Analyte Sensor
Bansod et al. Comparative study of current approaches for minimally invasive and non-invasive blood glucose monitoring

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2366746

Country of ref document: CA

Ref country code: CA

Ref document number: 2366746

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/009830

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 608939

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000919932

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000919932

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09937865

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000919932

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载